Liberum Capital restated their buy rating on shares of Reckitt Benckiser Group (LON:RB) in a research note released on Tuesday, October 30th. Liberum Capital currently has a GBX 7,600 ($99.31) price objective on the stock.
RB has been the topic of several other reports. Morgan Stanley restated a buy rating on shares of Reckitt Benckiser Group in a research report on Tuesday, October 16th. Barclays reiterated an equal weight rating and set a GBX 6,450 ($84.28) price target on shares of Reckitt Benckiser Group in a research report on Tuesday, September 4th. JPMorgan Chase & Co. reiterated an overweight rating and set a GBX 9,000 ($117.60) price target on shares of Reckitt Benckiser Group in a research report on Thursday, October 25th. Credit Suisse Group reiterated an underperform rating on shares of Reckitt Benckiser Group in a research report on Thursday, August 23rd. Finally, Goldman Sachs Group set a GBX 7,025 ($91.79) price target on Reckitt Benckiser Group and gave the company a neutral rating in a research report on Monday, October 8th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of GBX 7,054.74 ($92.18).
Shares of LON RB traded down GBX 81 ($1.06) during mid-day trading on Tuesday, hitting GBX 6,622 ($86.53). The company had a trading volume of 765,201 shares, compared to its average volume of 1,720,000. Reckitt Benckiser Group has a 12 month low of GBX 5,562 ($72.68) and a 12 month high of GBX 8,110.43 ($105.98).
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Further Reading: Investing in Dividend Stocks
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.